EGFR and non-small cell lung carcinoma: A phase 1b/2 trial (NCT02630186) aims to evaluate the safety and efficacy of rociletinib administered in combination with MPDL3280A.The primary purpose of the Phase 1 portion of the study is to observe the safety of the combination of rociletinib and MPDL3280A in patients with EGFR mutation-positive NSCLC.